A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity.
Level 3 - non-randomized controlled study
Controlled pilot study comparing GLP-1RA users to controls during an alcohol challenge
PubMed 41093891 · doi:10.1038/s41598-025-17927-w
What was done
In a pilot study, 20 participants with obesity (divided 1:1 between a GLP-1 receptor agonist group and a control group) ingested a challenge dose of alcohol. Researchers evaluated peripheral pharmacokinetics by measuring breath alcohol concentration (BrAC) and assessed subjective perceptual effects of alcohol.
What was found
Participants in the GLP-1RA group demonstrated a delayed rise in breath alcohol concentration and a delayed onset of subjective alcohol effects compared with controls. This delay was not explained by nausea. The abstract reports no numerical values, kinetic parameters, or statistical effect estimates.
Why it matters
This study provides preliminary evidence that GLP-1 receptor agonists may alter peripheral alcohol pharmacokinetics, suggesting a physiological mechanism for observed reductions in alcohol consumption.
Limits
The sample size is very small (n = 20 total). The abstract does not provide quantitative data, confidence intervals, or p-values, nor does it state the specific GLP-1RA agent, dosage, or whether allocation was randomized. Clinical drinking outcomes and long-term behavioral effects were not assessed.
Cited by
- supports GLP-1 receptor agonists slow gastric emptying, causing ingested alcohol to remain in the stomach longer.